Obesity constitutes a major global healthcare challenge. The morbidity, mortality, and socioeconomic costs of obesity are considerable. No currently available medical therapy delivers substantial, sustainable weight loss. The need to better understand the mechanisms of appetite regulation is therefore clear. Over the last 20 years, peptide hormones released from the gastrointestinal tract in response to nutritional stimuli have come to be recognized as important physiological regulators of appetite. Hormones such as peptide YY, pancreatic polypeptide, glucagon-like peptide-1 and oxyntomodulin are thought to act as postprandial satiety signals. These physiological pathways of appetite control offer a promising basis for anti-obesity therapies. Here, we briefly review the state of current knowledge of these hormones' actions on brain appetite circuits, and prospects for future research and development.
Introduction
Obesity has featured in the writings of chroniclers as diverse as Pliny the Younger, Samuel Johnson and Charles Dickens. We may infer from this that obesity has afflicted humans throughout recorded history. Nevertheless, by all currently accepted indicators, recent times have seen an unprecedented rise in the prevalence of obesity and overweight, prompting reference by the World Health Organization in its Global Strategy on Diet, Physical Activity and Health to a worldwide obesity epidemic. 1 The personal, societal and economic consequences of a continued unchecked rise in obesity are well documented. 2 However, currently licensed non-surgical interventions are of limited efficacy, 3, 4 and this has stimulated interest in harnessing the physiological mechanisms of energy homeostasis. The past 20 years have seen significant advances in our understanding of the mechanisms of control of appetite and energy intake. In particular, there has been a growing awareness that hormonal signals released from the gastrointestinal (GI) tract interact with central nervous system (CNS) circuits of appetite regulation. As a physiological signaling mechanism that is engaged repeatedly throughout the lifetime of an individual, this gut-brain axis constitutes a promising target for therapeutic intervention while avoiding the side effects that occur as an unwanted consequence of therapies targeting ubiquitous neurotransmitter and receptor complexes.
The gut-brain axis
Lines of communication between the GI tract and CNS therefore constitute a key mechanism by which appetite is regulated. The gut-brain axis has both neuronal and humoral components which relay information to CNS centers including the hypothalamus and brainstem. 5 These CNS structures have extensive reciprocal connections and both receive neuronal input from the periphery, the brainstem-vagus nerve complex being of particular significance in the control of feeding. 6, 7 Neuronal activity in the hypothalamus and brainstem is influenced by circulating hormones. In the hypothalamic arcuate nucleus, signals from the periphery result in changes in the relative activity of two subpopulations of neurones: an orexigenic population co-expressing the neurotransmitters neuropeptide Y and agouti-related peptide, and an anorexigenic population co-expressing pro-opiomelanocortin and cocaine-and amphetamine-regulated transcript. Alterations in the release of these neuropeptides affect feeding behavior and energy expenditure, resulting in the maintenance of energy homeostasis.
There is some doubt over the precise mechanisms by which hormones interact with CNS appetite centers. The proximity of both the hypothalamus and brainstem to structures with a relative deficiency of blood-brain barrier (the median eminence in the case of the hypothalamus and the area postrema in respect of the brainstem) may allow circulating factors direct access to CNS neurones. There is a growing body of evidence, however, that points to the vagus nerve as a primary site of action of some appetite-modulating hormones. [8] [9] [10] From a therapeutic perspective, targeting the interaction of appetite signals with their receptors in the vagus nerve offers the potential advantage of being able to manipulate appetite at a site distant from the CNS.
Gut hormones
The principle physiological role of gut peptides is to optimize the process of digestion and nutrient absorption. By controlling the rate at which nutrients are delivered to different gut compartments, the regulation of appetite may be regarded as another means by which digestion and nutrient absorption may be influenced. It is therefore logical that gut hormones are key players in appetite control.
Cholecystokinin was the first to be implicated in the shortterm control of food intake, 11 and other appetite-regulating hormones have subsequently been characterized. Of these, ghrelin is the only known orexigenic gut hormone, whereas a number of satiety factors exist, including glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM), peptide YY (PYY) and pancreatic polypeptide (PP). An exhaustive review of these hormones' effects and physiological role is beyond the scope of this paper, and the interested reader is referred elsewhere. 5, 12, 13 However, briefly, these gut hormones act as meal initiators and terminators. Their role as agents of appetite regulation has been investigated by both observational and interventional studies. Characterization of the release patterns of different gut hormones in relation to nutrient ingestion can provide insights into their effects on appetite. Furthermore, alterations in levels of gut hormones following bariatric surgery may contribute to the appetite suppression and sustained weight loss seen in patients undergoing this procedure and supports the development of these hormones as therapeutic targets. 14,15 Administration of exogenous peptide to animal models and human volunteers, and measurement of their effect on food intake, also illuminates the actions of these hormones on appetite. Glucagon-like peptide-1, OXM, PYY and PP will be considered in greater detail below as illustrative of many of the principles that have driven recent advances in our understanding of the processes of appetite regulation.
Glucagon-like peptide-1 Glucagon-like peptide-1 is a product of proglucagon cleavage and is released from the L-cells of the GI tract post-prandially in proportion to the amount of energy ingested. GLP-1 and longer-acting GLP-1 receptor agonists, such as exendin-4, reduce food intake in rodents when injected into the CNS 16 or peripherally. 9, 17 Clinical development has thus far focused on this hormone's potent incretin effect and its resultant use as an anti-diabetic agent. However, in contrast to insulin, GLP-1 results in a tendency to reduce body weight. 18 The advantages of a hypoglycemic agent that also promotes weight loss are obvious.
A major hurdle to the therapeutic use of native GLP-1, and one common to many gut hormones, is its short circulating half-life. Metabolism by the enzyme dipetidyl peptidase IV (DPP-IV) is the principal means by which circulating GLP-1 is inactivated. A number of DPP-IV-resistant GLP-1 receptor agonists, such as liraglutide (Novo Nordisk, Denmark) and exenatide (Byetta, Amylin Pharmaceuticals Inc., San Diego, CA, USA) have therefore been developed and are currently in various stages of testing as agents for the treatment of diabetes and obesity.
Oxyntomodulin
Another product of the tissue-specific differential cleavage of proglucagon, OXM is co-secreted with GLP-1 and PYY 3À36 into the circulation by intestinal L-cells following nutrient ingestion. OXM is a satiety signal and administration reduces energy intake in both rodents and humans. [19] [20] [21] Indeed, pre-prandial subcutaneous administration of OXM to overweight and obese humans over a 4-week period resulted in a significant reduction in body weight of 2.3 kg, compared with 0.5 kg for the placebo arm. 21 In addition, OXM has been found to have a beneficial effect on energy usage, in that it increased activity levels back toward 'normal' in overweight and obese volunteers. 22 Longer-term trials are now required to determine whether its beneficial combination of properties can be sustained. Like GLP-1, OXM is inactivated in a large part by DPP-IV and its advancement as a clinically useful treatment will be reliant upon the development of a breakdown-resistant analog.
Inhibitors of dipeptidyl peptidase IV
Another approach that has been adopted in the manipulation of the gut-brain axis to treat obesity is that of augmenting the effectiveness of endogenous gut peptides. However, the effect on weight of DPP-IV inhibitors is equivocal. A number of DPP-IV inhibitors are at various stages of development as therapies. The evidence from clinical trials to date suggests that, although well tolerated, these agents have little effect on weight. 23 Longer-term data are awaited.
Peptide YY Peptide YY 3À36 , the major circulating form of PYY, is co-secreted from intestinal L-cells with GLP-1 and OXM.
Although there was initially some contention regarding the effects of PYY 3À36 on energy intake in animal models, 24 a
number of research groups have demonstrated that peripheral PYY 3À36 inhibits food intake and reduces body weight gain in several species. [25] [26] [27] [28] [29] [30] In the first study of the effects of PYY 3À36 on food intake in humans, spontaneous food intake was reduced by 30% at plasma levels similar to those seen physiologically. 25 A further recent study observed a dosedependent reduction in appetite and food intake in response to intravenous PYY 3À36 administration in normal weight volunteers, although nausea occurred at higher doses. 30 It has been suggested that obesity is a PYY 3À36 -deficient state, with lower basal levels and a blunted post-prandial response. PYY 3À36 'replacement' would therefore seem an apposite therapy for obesity, and there is evidence that obese individuals retain sensitivity to its appetite-suppressant effects. 26 However, the therapeutic potential of PYY 3À36 as an anti-obesity treatment is currently unknown, as there are limited data regarding the effect of repeated doses of PYY 3À36 on body weight in humans. In one study, preprandial use of PYY 3À36 delivered through the intranasal route for 6 days in 37 obese volunteers was associated with significant reductions in daily energy intake that were sustained over the study period. Thrice daily administration of the peptide yielded a reduction in energy intake of 2713 kJ and weight loss of 0.6 kg after 6 days of treatment. 31 The results of more extensive trials are awaited.
Pancreatic polypeptide
Sharing some common structural features with PYY 3À36 , PP is principally secreted by a population of cells located at the periphery of pancreatic islets. It is released into the circulation in response to nutrient ingestion and is subject to control by the vagus nerve and a number of other factors. 5, 13 The role of PP in the regulation of energy balance is unclear. Studies have shown that circulating levels are reduced in the context of obesity, and there is abnormal release following a meal, 32 whereas levels are elevated in anorexic patients. 33 However, these findings have not been universally replicated. 34, 35 PP reduces food intake when administered to rodents and humans. 36, 37 It remains to be evaluated whether this effect is preserved in obese humans. Work in those with Prader-Willi syndrome, characterized by overeating and morbid obesity, is encouraging, 38 but not necessarily applicable to the more general, non-syndromic obese population.
Concluding remarks
Even modest weight loss, such as that resulting from the use of currently available therapies, can result in improvements in morbidity and life expectancy. 4 However, projections of future trends in the prevalence of obesity underline the urgent need for more effective treatments if the attendant socioeconomic consequences are to be lessened. The mechanisms of postprandial satiety are still being characterized. However, the recognition in the last 20 years that hormones secreted by the GI tract in response to nutritional stimuli are important physiological regulators of appetite offers a potentially rewarding strategy in the development of more effective anti-obesity agents. What, then, of the next 20 years? Might we reasonably expect gut hormone-based therapies for obesity to have crossed over from bench to bedside? The regulation of food intake is complex, and although its role is significant, the gut-brain axis operates alongside other components including CNS reward pathways, input from higher centers, societal and environmental influences. The homeostatic system has developed with a high degree of in-built redundancy to guard against starvation.
Of course, individual gut peptides are not released in isolation in response to nutrient ingestion. Rather, there is a coordinated release of a number of GI hormones, which act additively in orchestrating efficient nutrient absorption and meal termination. 39 It therefore seems not unreasonable to propose that in the therapeutic targeting of appetite regulation, polypharmacy with a number of therapies might maximize clinical effect while minimizing side effects, mirroring trends in the management of other chronic conditions such as hypertension. 40 Furthermore, as with current medical therapies for obesity, the greatest weight loss is likely to be seen within the context of a multidisciplinary approach incorporating effective lifestyle interventions. Investment in a strategy that involves lifestyle, behavioral, public health, medical and, where appropriate, surgical interventions would appear to be the most practical course to adopt. Within that framework, by exploiting the body's own satiety signals, drugs based on the actions of gut hormones will undoubtedly have a crucial role to play.
